This page contains a collection of published research pieces, outlining the details of our work over the past 20+ years in Parkinson's disease care.


How is this protocol approach different?

Standard medical treatment recognizes only one thing as most being the most effective Parkinson’s disease treatment available, L-dopa. All other approaches are not as effective.

Mayo Clinic on L-Dopa  Cleveland Clinic on L-dopa

When appropriate our doctors prescribe care that is based on two recently published double-blind studies posted by the National Institute of Health (NIH) on its website. The NIH position is that this alternative approach to Parkinson’s disease without carbidopa or benserazide is “similar to” or “as effective and safe as” L-dopa with carbidopa or L-dopa with benserazide.

In utilizing this NIH recognized approach, our approach is unique. It goes beyond the standard approach of administering one amino acid. This practice that can deplete other systems causing induction of multiple nutritional deficiencies. The approach used by our doctors addresses the 29 causes of nutritional deficiency associated with Parkinson’s disease, L-dopa, and carbidopa.

While the foundation of our patient care utilizes an approach recognized by the National Institute of Health as “similar to” or “as effective and safe as” L-dopa with carbidopa or L-dopa with benserazide, our overall approach is unique. It addresses the 29 causes of nutritional deficiency that can be associated with Parkinson’s disease, L-dopa, and carbidopa.

29 Causes of Nutritional Deficiency

Our approach does not use carbidopa or benserazide which improves Parkinson’s disease management in the following ways:

1.) Carbidopa can deplete vitamin B6

Depletion Paper 1  Depletion Paper 2  Depletion Paper 3

2.) Vitamin B6 depletion increases the death rate when all causes are considered.

B6 Death Rate Paper #1  B6 Death Rate Paper #2

3.) Removes concerns that Parkinson’s disease, L-dopa, and carbidopa can induce nutritional deficiencies whose symptoms are identical to Parkinson’s disease symptoms getting worse.

Nutritional Deficiency Symptoms Identical to Parkinson’s Disease Symptoms

4.) Removes concerns that carbidopa may accelerate fat soluble neurotoxin-induced brain damage secondary to glutathione collapse from carbidopa-induced vitamin B6 depletion. 

Glutathione Depletion in Parkinson’s Disease

5.) As noted in our peer-reviewed writings posted by the National Institute of Health on its website, nutrients when administered properly have no side effects. Removes concerns that L-dopa and carbidopa may induce nutritional depletion side effects which in turn is evidence of converting the nutrients to a drug.

Drug-nutrient Perspective

6.) Removes concerns that carbidopa depletion of vitamin B6 may interfere with the function of over 300 enzymes and proteins.

Vitamin B6 is Required for 300 Enzymes and Proteins as Posted on National Institute of Health

7.) Removes concerns that symptoms previously thought to be L-dopa induced permanent and irreversible dyskinesias and choreiform movement disorder are not and are now manageable during treatment.

Carbidopa-Induced Dyskinesias as Posted on the National Institute of Health Website

8.) Removes concerns relating to a potential link between carbidopa, vitamin B6 depletion and the increasing Parkinson’s disease death rate (See the “Our Unique Approach” page on this website).

The approach we have developed is not a self-treatment approach on any level. Even medical doctors who have Parkinson’s disease, who are actively caring for Parkinson’s disease patients are unable to achieve optimal results with self-treatment. Improper administration of these nutrients can induce other deterioration and nutritional deficiencies.

The Non-Scientific Approach

Three medical doctors worked several hours a day, every day for three months to write the carbidopa B6 death paper. The death data from the Center for Disease control took many hours to analyze. We are aware of an individual with no medical license and a loud website who contacted the Centers for Disease Control after reading our carbidopa B6 death paper. He found out we were correct with the death data. He then claimed the CDC communicated him the increase in death rate could be from more people diagnosed with Parkinson’s disease. This one is like comparing apples and oranges. The data we reported was the prevalence of patients with Parkinson’s disease per 100,000. This data is not affected by diagnosing more patients. For example, if six patients in 1,000 people have a disease, then 60 patients in 10,000 will have the disease. Diagnosing more patients has nothing to do with what we have reported. Loud websites throwing around facts like this only serves to confuse people looking for valid information. The non-medical owner of the website’s observations is only smoke and mirrors as covered in the next paragraph.

Establishing Validity

The proper approach for expressing disagreement with a formal scientific paper is writing a formal peer-reviewed rebuttal, in this case to the National Institute of Health standards. There has been no formal scientific challenge to this paper. Those with interests in protecting these drugs at all cost, independent of the facts, have posted smoke and mirror internet opinions that are not formal scientific writings. We are aware of the embellishment of second-hand facts not related to the science discussed on this webpage that has brought people reading them to anger. Everyone, take a deep breath. These are important observations which need attention. Our papers meet the National Institute of Health (NIH) standard for classification as peer-reviewed scientific medical papers. No one person wrote the six Parkinson’s disease papers. For these papers to be published required, seven medical doctor authors, eighteen medical doctor peer-reviewers and two editors-in-chief, twenty-seven highly skilled and highly trained people had to approve of the contents before publication.

For more information on our approach to Parkinson’s disease send an email to This email address is being protected from spambots. You need JavaScript enabled to view it. or call 218-626-2220. After you send your email, we may ask for more information. All communications will be kept confidential. If you have any questions, please call us free of charge.

The following are the peer-reviewed scientific papers we have published. Do a Google search using the article name to downloads a full-text version of each article.

  1. Trachte, G. Uncini, T. Hinz, M, Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population Neuropsychiatric Disease and Treatment, 2009, 5:227–2358.

  2. Hinz, M. Depression In: Kohlstadt I. editor. Food and Nutrients in Disease Management CRC Press; 2009, 465-481

  3. Hinz, M. Stein, A, Uncini T. The dual-gate lumen model of renal monoamine transport Neuropsychiatric Disease and Treatment, 2010, 6 387–392
  4. Hinz, M. Stein, A, Trachte, G, Uncini T. Neurotransmitter testing of the urine; a comprehensive analysis. Open Access Journal of Urology 2010:2 177–183

  5. Hinz, M. Stein, A. Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole, NeuroPsychiatric Disease and Treatment Neuropsychiatric Disease and Treatment: 2010, 6:741–747

  6. Stein, A. Hinz, M. Uncini T. Amino acid responsive Crohn’s disease, a case study. Clinical and Experimental Gastroenterology 2010:3 171–177

  7. Hinz, M. Stein A. Uncini T. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation Neuropsychiatric Disease and Treatment 2011:7 31–38

  8. Hinz, M. Stein, A. Uncini T. Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine Open Access Journal of Urology 2011:3 19–24

  9. Hinz, M. Stein, A. Uncini T. Amino acid management of Parkinson disease: A case study International Journal of General Medicine 2011:4 1–10

  10. Hinz, M. Stein, A. Uncini T. Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model” International Journal of Nephrology and Renovascular Disease 2011:4 101–113

  11. Stein, A. Hinz, M. Uncini T. Microperforation prolotherapy: a novel method for successful nonsurgical treatment of atraumatic spontaneous anterior sternoclavicular subluxation, with an illustrative case Open Access Journal of Sports Medicine 2011:2 47–52

  12. Hinz, M. Stein, A. Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction Neuropsychiatric Disease and Treatment 2011 2011:7 1–7

  13. Hinz, M. Stein, A. Uncini T. Monoamine depletion by reuptake inhibitors International Drug, Healthcare and Patient Safety 2011:3 69–77

  14. Hinz, M. Stein, A. Uncini T. The discrediting of the monoamine hypothesis International Journal of General Medicine 2012:5 135–142

  15. Hinz, M. Stein, A. Uncini T. Relative nutritional deficiencies associated with centrally acting monoamines. International Journal of General Medicine approved March 2012 for publication status in press.

  16. Hinz, M. Stein, A. Uncini T. 5-HTP efficacy and contraindications. International Journal of General Medicine 2012:5 413–430

  17. Hinz, M. et. al. Administration of Supplemental L-tyrosine with Phenelzine: A Clinical Literature Review. Clinical Pharmacology: Advances and Applications 2014:6 107–110 22 July 2014

  18. Hinz, M. et. al. Management of L-dopa overdose in the competitive inhibition state Drug, Healthcare and Patient Safety 2014:6 93–99 22 July 2014

  19. Hinz M. et. al. The Parkinson’s disease death rate Clinical Pharmacology: Advances and Applications 2014:6 161–169 21 October 2014

  20. Hinz, M. et. al. Parkinson’s disease: nausea and dyskinesia Clinical Pharmacology: Advances and Applications 2014:6 189–194 14 November 2014

  21. Hinz, M. et. al. Parkinson’s disease-associated melanin steal Neuropsychiatric Disease and Treatment 2014:10 2331–2337 10 December 2014

  22. Hinz, M. et. al. Parkinson’s disease managing reversible neurodegeneration Neuropsychiatric Disease and Treatment 2016:12 763–775 5 April, 2016

Would you like more information on our unique approach to Parkinson's disease care?